Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone.

[1]  R. Dietz,et al.  The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. , 2000, The Journal of clinical endocrinology and metabolism.

[2]  G. Van den Berghe,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 2000, The New England journal of medicine.

[3]  R. Demling.  Growth hormone therapy in critically ill patients. , 1999, The New England journal of medicine.

[4]  F. Minuto,et al.  Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. , 1999, The American journal of cardiology.

[5]  M. Volterrani,et al.  Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. , 1999, American heart journal.

[6]  P. Ponikowski,et al.  Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. , 1999, European heart journal.

[7]  S. Anker,et al.  Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. , 1999, Chest.

[8]  J. Ross.  Growth hormone, cardiomyocyte contractile reserve, and heart failure. , 1999, Circulation.

[9]  T. Voigtländer,et al.  Recombinant growth hormone therapy in patients with ischemic cardiomyopathy : effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. , 1999, Circulation.

[10]  M. Lomsky,et al.  A placebo-controlled study of growth hormone in patients with congestive heart failure. , 1998, European heart journal.

[11]  J. Kehayias,et al.  Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. , 1998, Journal of veterinary internal medicine.

[12]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[13]  P. Poole‐Wilson,et al.  Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy , 1998, The Lancet.

[14]  K. Matuszewski,et al.  Recombinant Human Growth Hormone for AIDS-Associated Wasting , 1998, The Annals of pharmacotherapy.

[15]  B. Lindholm,et al.  Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. , 1998, Kidney international.

[16]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[17]  K. Loon.  SAFETY OF HIGH DOSES OF RECOMBINANT HUMAN GROWTH HORMONE , 1998 .

[18]  S. Anker,et al.  Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. , 1997, Journal of the American College of Cardiology.

[19]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[20]  D. Green,et al.  Treatment of end-stage cardiac failure with growth hormone , 1997, The Lancet.

[21]  M. Volterrani,et al.  Haemodynamic effects of intravenous growth hormone in congestive heart failure , 1997, The Lancet.

[22]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[23]  P. Poole‐Wilson,et al.  The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. , 1997, European heart journal.

[24]  H. Orskov,et al.  Abdominal fat determines growth hormone-binding protein levels in healthy nonobese adults. , 1997, The Journal of clinical endocrinology and metabolism.

[25]  L. Saccá,et al.  Cardiovascular effects of GH. , 1997, The Journal of endocrinology.

[26]  M. Ranke,et al.  Diagnostics of endocrine function in children and adolescents , 2003 .

[27]  R. Ross,et al.  Growth hormone therapy for protein catabolism. , 1996, QJM : monthly journal of the Association of Physicians.

[28]  J. Wass,et al.  Growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[29]  C. Strasburger,et al.  Immunofunctional assay of human growth hormone (hGH) in serum: a possible consensus for quantitative hGH measurement. , 1996, The Journal of clinical endocrinology and metabolism.

[30]  N. Skakkebaek,et al.  Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol‐induced liver disease , 1996, Hepatology.

[31]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[32]  T. Clackson,et al.  Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. , 1995, The New England journal of medicine.

[33]  R. Ross,et al.  Acquired growth hormone resistance. , 1995, European journal of endocrinology.

[34]  I. Godsland,et al.  Insulin resistance in chronic heart failure. , 1994, European heart journal.

[35]  Moxley Rt rd.  Potential for growth factor treatment of muscle disease. , 1994 .

[36]  R. Moxley.  Potential for growth factor treatment of muscle disease , 1994, Current opinion in neurology.

[37]  B. Breier,et al.  Radioimmunoassays for IGFs and IGFBPs. , 1994, Growth regulation.

[38]  P. Kelly,et al.  Evidence for generation of the growth hormone-binding protein through proteolysis of the growth hormone membrane receptor. , 1993, Endocrinology.

[39]  R. Ross,et al.  Acquired growth hormone resistance in patients with hypercatabolism. , 1993, Hormone research.

[40]  E. Rutanen,et al.  Insulin-like growth factors and their binding proteins. , 1990, Acta endocrinologica.

[41]  P. Gluckman,et al.  Insulin-like growth factor-1 (IGF-1) in mice reduces weight loss during starvation. , 1989, Endocrinology.

[42]  P. Sönksen,et al.  CARDIAC FAILURE RESPONDING TO GROWTH HORMONE , 1989, The Lancet.

[43]  E. Froesch,et al.  Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. , 1987, The New England journal of medicine.